Speech Predicts Alzheimer’s; Afib and Dementia in Women; Who Gets Lecanemab?

Automated detection of speech changes in early Alzheimer’s may predict disease progression, a longitudinal analysis suggested. (Alzheimer’s & Dementia)

More blood pressure-lowering medications than those included in treatment guidelines reduced episodic migraine frequency. (Cephalalgia)

Olfactory dysfunction raised the risk of subsequent depressive symptoms. (Journals of Gerontology: Series A)

Cholinesterase inhibitors were tied to small improvements on delusions and hallucinations in Alzheimer’s disease and Parkinson’s disease, a meta-analysis suggested. (JAMA Neurology)

Atrial fibrillation was associated with more rapid progression to mild cognitive impairment and dementia in women. (Alzheimer’s & Dementia)

The FDA approved argenx’s injectable efgartigimod alfa (Vyvgart Hytrulo) for generalized myasthenia gravis patients who are anti-acetylcholine receptor antibody positive, Halozyme Therapeutics said.

CMS announced new details of its plan to cover new Alzheimer’s drugs.

Experts discussed who might get lecanemab (Leqembi) if the anti-amyloid Alzheimer’s drug wins full FDA approval next week — and who might not. (NPR)

The Semont-plus maneuver was superior to the Epley maneuver in terms of the number of days until recovery in posterior canal benign paroxysmal positional vertigo. (JAMA Neurology)

New multiple sclerosis (MS) lesions that evolved into paramagnetic rim lesions may be identified early. (Annals of Neurology)

People with progressive MS had a higher risk of severe COVID-19 than those with relapsing remitting MS (RRMS), and anti-CD20 therapies in RRMS were associated with severe COVID-19. (JAMA Network Open)

A multilevel analysis of the gut-brain axis showed links between autism spectrum disorder and specific microbial profiles. (Nature Neuroscience)